智通财经APP讯，诺诚健华(09969)公布，CP-488用于治疗中重度斑块状银屑病的II 期研究数据已于2025年美国皮肤病学会(AAD)年会上公布，该学会是皮肤科领域最具影响力的国际盛会，相关数据以重磅口头报告形式发表。
研究结果表明，ICP-488在每天一次(QD)6毫克和每天一次9毫克的剂量下对银屑病患者均具有显著疗效，且展现出良好的安全性和耐受性，为中重度银屑病患者提供了有价值的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.